Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL

Bristol-Myers Squibb CompanyBristol-Myers Squibb Company (NYSE: BMY) has signed agreements with ICON and PAREXEL, two leading providers of clinical development services to the biopharmaceutical industry, for joint strategic, operational and capability support of the company's clinical development program.

Under the agreements, ICON and PAREXEL will provide global support for the execution of Bristol-Myers Squibb's clinical studies to support its full development pipeline over the next three years. Because of a robust pipeline and significant inlicensing activity, Bristol-Myers Squibb is preparing for a large volume of clinical development work that will require expanding upon its existing partnering approach for clinical development. Consistent with the company's BioPharma strategy, the agreements with ICON and PAREXEL will complement the company's internal high-performing capabilities and capacity with high-quality clinical development services from partners who can drive efficiency and cost savings.

"These partnerships will increase the operational capability of our clinical development organization, and support our industry-leading position in productivity and innovation," said Brian Daniels, senior vice president, Global Development, Bristol-Myers Squibb. "Working with ICON and PAREXEL, two leaders in clinical research, Bristol-Myers Squibb will enhance support for our robust pipeline and improve our ability to deliver innovative medicines to patients with serious disease."

"We are delighted that Bristol-Myers Squibb has selected us to support its global clinical development programs," commented Dr. John Hubbard, ICON Group President Clinical Research Services. "Over the last ten years, we have forged a strong partnership by working hard to fully understand Bristol-Myers Squibb's unique requirements. We look forward to moving this partnership to another level and continuing to support Bristol-Myers Squibb's goal of bringing innovative treatments to patients."

"We look forward to a deeply collaborative relationship with Bristol-Myers Squibb to help provide innovative solutions for its growing pipeline, as well as leverage our global capabilities and worldwide technology infrastructure to support the effectiveness of its clinical development programs," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. "PAREXEL is proud to join this partnership, which is representative of leading models for outsourcing that have the potential to increase efficiency and create significant value."

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...